Lyra Therapeutics reports Q2 EPS ($5.51), consensus ($4.78)

Reports Q2 revenue $183,000, consensus $181,250. “The positive results from our ENLIGHTEN 2 trial have enabled us to secure financing and are providing momentum to optimize our regulatory strategy and resume manufacturing activities, as we pursue our path to advance LYR-210 as a six-month treatment option for millions of patients who do not respond to standard CRS medical management,” said Maria Palasis, president and CEO, Lyra Therapeutics (LYRA), Inc. “We continue to review and analyze the totality of the dataset from the ENLIGHTEN 1 and ENLIGHTEN 2 trials as we execute on our business strategy and envision the opportunities ahead for LYR-210 to benefit patients with CRS.”